Tsianakas A, et al. – The efficacy of dupilumab treatment was examined for health–related quality of life (HRQoL) in patients with moderate–to–severe atopic dermatitis (AD). Results confirmed that dupilumab improved QoL Index for AD (QoLIAD) scores in adults with AD.

Methods

• Patients were randomized to receive 300 mg weekly subcutaneous dupilumab or placebo for 12 weeks.
• In 64 adults with moderate–to–severe AD, the QoL Index for AD (QoLIAD) score (exploratory outcome) and its correlation with efficacy outcomes (Eczema Area and Severity Index [EASI; primary endpoint], SCORing Atopic Dermatitis [SCORAD], SCORAD visual analogue scale [VAS] scores for sleep and pruritus, pruritus numerical rating scale [NRS] and 5–dimensional pruritus) were evaluated.

Results

• Mean QoLIAD scores at baseline (± standard error [SE]) were 13.3 (±1.34) and 11.3 (±1.09) for the placebo and dupilumab group, respectively.
• After 12 weeks of treatment, dupilumab significantly improved QoLIAD score compared to placebo (mean percent change from baseline in QoLIAD score [±SE]: –64.0 [±6.91] vs. –11.1 [±9.31]).
• Least squares mean % difference from baseline vs. placebo in QoLIAD score (±SE) was –52.0 (±11.43; P<0.0001).
• QoLIAD scores significantly correlated with changes in efficacy outcomes, including EASI (r=0.4355), 5–dimensional pruritus (r=0.4937), pruritus NRS (r=0.4064), total SCORAD (r=0.5559), and SCORAD VAS scores for sleep (r=0.4681) and pruritus (r=0.5400); all P<0.05.